https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34224 Tue 19 Mar 2019 11:56:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33786 -8 with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.]]> Thu 30 Mar 2023 15:49:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45092 BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM^−/− patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.]]> Thu 27 Oct 2022 15:50:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19135 Sat 24 Mar 2018 07:55:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5085 Sat 24 Mar 2018 07:48:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5450 Sat 24 Mar 2018 07:48:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5234 Sat 24 Mar 2018 07:44:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26588 Sat 24 Mar 2018 07:34:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4753 Sat 24 Mar 2018 07:21:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4800 Sat 24 Mar 2018 07:20:39 AEDT ]]>